FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040894076> ?p ?o ?g. }

• W3040894076 endingPage "S173" @default.
• W3040894076 startingPage "S173" @default.
• W3040894076 abstract "Pancreatic adenocarcinoma has one of the poorest survival rates, with median overall survival (OS) commonly ranging between 10 to 12 months. Lancet Oncology details that Australia, in particular Western Australia, has one of the best survival rates for pancreatic cancer globally given a 5-year net survival rate of 18.1%. This retrospective analysis:- 1. Examines overall survival rates of patients with locally advanced or metastatic pancreatic adenocarcinoma receiving treatment in Western Australia 2. Identifies factors that may contribute to pancreatic cancer patient survival time in Western Australia. A retrospective cohort study identified patients with locally advanced and metastatic pancreatic adenocarcinoma diagnosed between January 2014 and December 2019. All patients had an ECOG performance status of 2 or less. Patients’ treatment lines and modalities were collected and analysed. Overall survival (OS) was estimated via Kaplan-Meier method. A total of 157 patients were identified in our cohort. Out of these, 74 patients (47%) had metastatic disease. Patients were further identified as having the following treatment: chemotherapy only (70 patients), chemotherapy then chemo-radiotherapy (43 patients), chemotherapy and curgery (23 patients) and tri-modality (21 patients). Treatment lines for patients are as following:- a) Chemotherapy only – First line Gemcitabine/nab-Paclitaxel (Gem/NabP) (64 patients) was used, followed by second-line mFOLFIRINOX (48 patients), and third line re-treatment of Gem/NabP (6 patients). b) Chemotherapy then chemo-radiotherapy – Routine incorporation of infusional 5-Fluorouracil were performed for all patients undergoing radiotherapy, where first line Gem/NabP (39 patients) was used, followed by second line mFOLFIRINOX (18 patients), and third line re-treatment Gem/NabP (6 patients). c) Chemotherapy and surgery – First line Gem/NabP (11 patients) was used, followed by second-line mFOLFIRINOX (8 patients), and third line re-treatment of Gem/NabP (4 patients). d) Tri-modality – First line Gem/NabP (19 patients) was used, followed by second-line mFOLFIRINOX (13 patients), and third line re-treatment of Gem/NabP (5 patients). Overall survival (OS) of both locally advanced and metastatic pancreatic adenocarcinoma was 22.0 months (95% CI 20.0 – 28.0). Locally advanced disease patients had OS of 34.0 months (95% CI, 24.0 – 26.0) whereas metastatic disease patients had OS of 19.0 months (95% CI, 12.0 – 21.0). This retrospective study showed a significant prolonged overall survival for both locally advanced and metastatic pancreatic cancer, with the combined and individual median survival being vastly superior in comparison to global standards. The use of second-line mFOLFIRINOX, as well as third-line re-treatment with Gem/NabP in those of good performance status, could be influencing the overall survival rate." @default.
• W3040894076 created "2020-07-16" @default.
• W3040894076 creator A5015992547 @default.
• W3040894076 creator A5021083539 @default.
• W3040894076 creator A5022112281 @default.
• W3040894076 creator A5044483132 @default.
• W3040894076 creator A5052709676 @default.
• W3040894076 creator A5055243440 @default.
• W3040894076 creator A5065668767 @default.
• W3040894076 creator A5070773936 @default.
• W3040894076 creator A5072265166 @default.
• W3040894076 date "2020-07-01" @default.
• W3040894076 modified "2023-10-16" @default.
• W3040894076 title "P-256 Survival rates of locally advanced and metastatic pancreatic cancer in Western Australia" @default.
• W3040894076 doi "https://doi.org/10.1016/j.annonc.2020.04.338" @default.
• W3040894076 hasPublicationYear "2020" @default.
• W3040894076 type Work @default.
• W3040894076 sameAs 3040894076 @default.
• W3040894076 citedByCount "0" @default.
• W3040894076 crossrefType "journal-article" @default.
• W3040894076 hasAuthorship W3040894076A5015992547 @default.
• W3040894076 hasAuthorship W3040894076A5021083539 @default.
• W3040894076 hasAuthorship W3040894076A5022112281 @default.
• W3040894076 hasAuthorship W3040894076A5044483132 @default.
• W3040894076 hasAuthorship W3040894076A5052709676 @default.
• W3040894076 hasAuthorship W3040894076A5055243440 @default.
• W3040894076 hasAuthorship W3040894076A5065668767 @default.
• W3040894076 hasAuthorship W3040894076A5070773936 @default.
• W3040894076 hasAuthorship W3040894076A5072265166 @default.
• W3040894076 hasBestOaLocation W30408940761 @default.
• W3040894076 hasConcept C121608353 @default.
• W3040894076 hasConcept C126322002 @default.
• W3040894076 hasConcept C141071460 @default.
• W3040894076 hasConcept C143998085 @default.
• W3040894076 hasConcept C167135981 @default.
• W3040894076 hasConcept C2776283816 @default.
• W3040894076 hasConcept C2776694085 @default.
• W3040894076 hasConcept C2780210213 @default.
• W3040894076 hasConcept C2780258809 @default.
• W3040894076 hasConcept C2781182431 @default.
• W3040894076 hasConcept C509974204 @default.
• W3040894076 hasConcept C71924100 @default.
• W3040894076 hasConcept C72563966 @default.
• W3040894076 hasConceptScore W3040894076C121608353 @default.
• W3040894076 hasConceptScore W3040894076C126322002 @default.
• W3040894076 hasConceptScore W3040894076C141071460 @default.
• W3040894076 hasConceptScore W3040894076C143998085 @default.
• W3040894076 hasConceptScore W3040894076C167135981 @default.
• W3040894076 hasConceptScore W3040894076C2776283816 @default.
• W3040894076 hasConceptScore W3040894076C2776694085 @default.
• W3040894076 hasConceptScore W3040894076C2780210213 @default.
• W3040894076 hasConceptScore W3040894076C2780258809 @default.
• W3040894076 hasConceptScore W3040894076C2781182431 @default.
• W3040894076 hasConceptScore W3040894076C509974204 @default.
• W3040894076 hasConceptScore W3040894076C71924100 @default.
• W3040894076 hasConceptScore W3040894076C72563966 @default.
• W3040894076 hasLocation W30408940761 @default.
• W3040894076 hasOpenAccess W3040894076 @default.
• W3040894076 hasPrimaryLocation W30408940761 @default.
• W3040894076 hasRelatedWork W110408602 @default.
• W3040894076 hasRelatedWork W114644245 @default.
• W3040894076 hasRelatedWork W1971611596 @default.
• W3040894076 hasRelatedWork W2376347278 @default.
• W3040894076 hasRelatedWork W2391084975 @default.
• W3040894076 hasRelatedWork W2404042595 @default.
• W3040894076 hasRelatedWork W2780595932 @default.
• W3040894076 hasRelatedWork W3029364823 @default.
• W3040894076 hasRelatedWork W4246166499 @default.
• W3040894076 hasRelatedWork W3030467549 @default.
• W3040894076 hasVolume "31" @default.
• W3040894076 isParatext "false" @default.
• W3040894076 isRetracted "false" @default.
• W3040894076 magId "3040894076" @default.
• W3040894076 workType "article" @default.